News

Results from a study of tazemetostat in patients with BAP1-inactivated malignant pleural mesothelioma show the feasibility of molecularly-stratified therapy for patients with relapsed or refractory disease.

Developers of elacestrant are seeking FDA approval of the agent for the treatment of patients with ER-positive/HER2-negative advanced or metastatic breast cancer.

A retrospective analysis of next-generation sequencing data showed that the presence of pathogenic POLE mutations correlate with clinical benefit in immune checkpoint inhibitor therapy.

In an interview with Targeted Oncology, Adam Weiner, MD, discussed molecular subtyping for prostate cancer based on basal and luminal cell-of-origin and how such research may impact the future of this space.

In an interview with Targeted Oncology, Leonard A. Kalman, MD, discussed how real-world data will improve the understanding of patients with cancer being treated at Miami Cancer Institute and of how the business runs overall.

Christopher Melani, MD, discusses the unmet needs remaining in the mantle cell lymphoma space.

An investigational bivalent gB/pp65 immunotherapeutic vaccine candidate has been granted orphan drug designation by the FDA for the treatment of patients with glioblastoma.

The FDA has granted orphan drug designation to MB-106, for the treatment of patients with Waldenstrom macroglobulinemia. The agent is being investigated in a phase 1/2 clinical trial.

The FDA has granted accelerated approval to dabrafenib plus trametinib for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors who harbor a BRAF V600E mutation.

During an interview with Targeted Oncology, Nicholas J. Robert, MD, further discussed the data of the MYLUNG study which he presented in a poster at the 2022 American Society of Clinical Oncology Annual Meeting.

Alexander Drilon, MD, discussed NTRK gene fusions in solid tumors, collective findings of studies assessing larotrectinib for the treatment of these fusions, and how to conduct genomic testing to identify patients who might benefit from TRK inhibitor therapy.

Florida Cancer Specialists & Research Institute, LLC held a ribbon-cutting ceremony on June 16, 2022 to celebrate the opening of a new clinical site in Kissimmee, FL.

A member of Florida Cancer Specialists & Research Institute, LLC, has been selected as a recipient of the 40 Under 40 in Cancer Award.

Updated data from the CHiRP study demonstrates clinical potential with the RaDaR minimal residual disease test in patients with high-risk hormone receptor–positive human epidermal growth factor receptor 2-negative breast cancer.

Adding atezolizumab to first-line FOLFOXIRI with bevacizumab is shown to be a safe treatment option and improves progression-free survival in patients with metastatic colorectal cancer.

Eric Jonasch, MD, further discussed the 2 posters he presented in regard to belzutifan at 2022 ASCO.

Orphan drug designation has been granted by the FDA to PT217 for patients with small cell lung cancer.

In an interview with Targeted Oncology, Roger Li, MD, discussed the use of the CG0070 in combination with pembrolizumab and nivolumab for patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.

An investigational new drug application has been cleared by the FDA for NXP800 as treatment of various advanced cancers.

Improvement in progression-free survival and safety demonstrated with the addition of vistusertib to anastrozole vs anastrozole alone in patients with hormone receptor−positive recurrent or metastatic endometrial cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the unmet needs that are hoped to be filled by the phase 1/2 KRYSTAL-1 study.

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed the key takeaways of the updated safety analysis of the DESTINY-Breast03 trial.

Fast track designation has been granted by the FDA to dianhydrogalactitol for the treatment of patients with newly-diagnosed unmethylated glioblastoma.

Orphan drug designation has been granted to QXL138AM for the treatment of patients with pancreatic cancers.

Paxalisib has been granted orphan drug designation by the FDA for the treatment of patients with atypical rhabdoid or teratoid tumors in rare and aggressive childhood brain cancer.

Mazyar Shadman, MD, MPH, discusses the phase 1/2 clinical trial of MB-106 for patients with CD20 positive B-cell malignancies.

A manageable side-effect profile, signal of efficacy, and 36% increase in the recommended phase 2 dose (RP2D) was seen with a step-up dosing regimen of tebentafusp in patients with metastatic uveal melanoma.

Mark Markowski, MD, PhD, discusses the design of a phase 1B/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who have had treatment and progression on an androgen receptor–targeting agent.

The ASCO’s expert panel released updated recommendations of pembrolizumab in combination with neoadjuvant chemotherapy for patients with stage II or stage III early triple-negative breast cancer

Enrollment has been completed for the phase 3 PRESERVE 1 trial of trilaciclib in patients with metastatic colorectal cancer receiving chemotherapy.